Takeda Calls Abrupt Halt To Phase III Trials Of Sepsis Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical stopped the Phase III trials of its TAK-242 drug for treating sepsis, but said it was not because of safety or efficacy reasons. The company said it is dropping the drug for strategic reasons, but without elaboration other than the time and investment needed to complete the trials. A spokesman said the firm could decide to license the drug, which already had fast-track review status at the U.S. FDA, to other manufacturers. (Click here for more - a subscription may be required
|
Takeda Pharmaceutical stopped the Phase III trials of its TAK-242 drug for treating sepsis, but said it was not because of safety or efficacy reasons. The company said it is dropping the drug for strategic reasons, but without elaboration other than the time and investment needed to complete the trials. A spokesman said the firm could decide to license the drug, which already had fast-track review status at the U.S. FDA, to other manufacturers. (Click here for more - a subscription may be required) "Takeda Discontinues Global Development Of Sepsis Drug" - Nikkei (Japan) (2/20/09) |